The FDA lifting the clinical hold on Foghorn Therapeutics' Phase 1 study of FHD-286 is a positive development for the company. This allows them to proceed with their research and commence a new study in Q3 2023, which could potentially lead to positive results and increased investor interest in the stock. The news is highly relevant and important for investors in FHTX, and the confidence in the analysis is high due to the direct impact of the FDA's decision on the company's research progress.